In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Seres Health brings in $65mm via Series D

Executive Summary

Just one month after closing a $48mm Series C round, Seres Health Inc. (microbiome therapeutics) raised $65mm in its Series D financing to Nestle Health Science. The proceeds will help move its lead compound SER109 for preventing the recurrence of Clostridium difficile infection into Phase III and to advance other pipeline candidates. Nestle Health’s CEO joins Seres Health’s board.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies